SYNB:NYE-Putnam Biorevolution ETF (USD)

ETF | Others |

Last Closing

USD 31.3946

Change

-0.04 (-0.13)%

Market Cap

USD 5.43M

Volume

223.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SOJE SOJE

-0.01 (-0.05%)

USD 65.72B
JEPI JPMorgan Equity Premium Income..

+0.02 (+0.04%)

USD 33.49B
DFAC Dimensional U.S. Core Equity 2..

+0.03 (+0.09%)

USD 28.45B
DTB DTB

+0.11 (+0.56%)

USD 26.58B
GBTC Grayscale Bitcoin Trust (BTC)

+0.39 (+0.72%)

USD 23.75B
JPST JPMorgan Ultra-Short Income ET..

+0.01 (+0.02%)

USD 23.71B
SGOV iShares® 0-3 Month Treasury B..

+0.01 (+0.01%)

USD 22.84B
AVUV Avantis® U.S. Small Cap Value..

+0.17 (+0.19%)

USD 11.21B
JAAA Janus Detroit Street Trust - J..

+0.01 (+0.02%)

USD 10.41B
DFUV Dimensional US Marketwide Valu..

-0.02 (-0.05%)

USD 10.31B

ETFs Containing SYNB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.88% 69% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.88% 65% D 65% D
Trailing 12 Months  
Capital Gain 15.43% 69% C- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.43% 66% D+ 63% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.61% 72% C 54% F
Dividend Return 3.61% 67% D+ 46% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.82% 71% C- 88% B+
Risk Adjusted Return 61.99% 81% B- 82% B
Market Capitalization 5.43M 12% F 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.